Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces ABBV-951 (Foslevodopa\/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa\/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Positive Phase 3 Atogepant (QULIPTA\u2122) Data for the Preventive Treatment of Chronic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa\/Foslevodopa) for the Treatment of Advanced Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AbbVie Inc"},{"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"TauRx Therapeutics"},{"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx's Late-Stage Clinical Trial Reaches New Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"TauRx Therapeutics"},{"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tau-Targeting Alzheimer's Treatment, HMTM, Moving Toward Regulatory Submission Based on Initial Data From TauRx's LUCIDITY trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"TauRx Therapeutics"}]

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease

Details:

The submission is based on results from a Phase 3 trial for ABBV-951 (Foscarbidopa/Foslevodopa) demonstrating statistically significant improvement in "On" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa.

Lead Product(s): Foslevodopa,Foscarbidopa

Therapeutic Area: Neurology Product Name: ABBV-951

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 20, 2022

Abbvie Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine

Details:

Pivotal Phase 3 study evaluating QULIPTA™ (atogepant) in adult patients with chronic migraine meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo across the 12-week treatment period.

Lead Product(s): Atogepant

Therapeutic Area: Neurology Product Name: MK 8031

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2022

Abbvie Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 ...

Details:

ABBV-951 (Foslevodopa/Foscarbidopa) is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion that is being investigated for the treatment of advanced Parkinson's disease in patients whose motor symptoms are not controlled by oral medications.

Lead Product(s): Levodopa,Carbidopa

Therapeutic Area: Neurology Product Name: ABBV-951

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 28, 2021

Abbvie Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress

Details:

Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine.

Lead Product(s): Atogepant

Therapeutic Area: Neurology Product Name: MK 8031

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 08, 2021

Abbvie Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine

Details:

If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine.

Lead Product(s): Atogepant

Therapeutic Area: Neurology Product Name: MK 8031

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2021

Abbvie Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®

Details:

Pivotal phase 3 study design evaluating the investigational medicine ABBV-951, a subcutaneous delivery of levodopa/carbidopa, for the patients with advanced Parkinson's disease will be be presented at the International Congress of Parkinson's Disease and Movement Disorders®.

Lead Product(s): Foslevodopa,Foscarbidopa

Therapeutic Area: Neurology Product Name: ABBV-951

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2020

Abbvie Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

Details:

Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period.

Lead Product(s): Atogepant

Therapeutic Area: Neurology Product Name: MK 8031

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 29, 2020

Abbvie Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

TauRx Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tau-Targeting Alzheimer's Treatment, HMTM, Moving Toward Regulatory Submission Based on Initial Data From TauRx's LUCIDITY trial

Details:

TauRx's lead investigative oral drug, TRx0237, has been tested in 598 people with Alzheimer's. Following our 12 month blinded phase of the study, participants have moved forward to an additional one year open label phase.

Lead Product(s): Hydromethylthionine

Therapeutic Area: Neurology Product Name: TRx0237

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

ASK
US

Upload
your Pipeline Activity

TauRx Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

TauRx's Late-Stage Clinical Trial Reaches New Milestone

Details:

This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM).

Lead Product(s): Hydromethylthionine

Therapeutic Area: Neurology Product Name: TRx0237

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2022

ASK
US

Upload
your Pipeline Activity

TauRx Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia

Details:

Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease.

Lead Product(s): Hydromethylthionine

Therapeutic Area: Neurology Product Name: TRx0237

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY